[Product/Solution] Industrialization of reactor-produced medical isotopes

1. Brief introduction of achievements

(1) Lutetium-177: Product indicators meet or exceed the European Pharmacopoeia standards, and the price is 20% lower than the import price.

(2) Strontium-89: It has been supplied to the Chinese market for five consecutive years, with a market share of more than 50% in China.

(3) Carbon-14: China's first company to produce and supply high-specific-activity carbon-14, and its product quality has reached the international advanced level.

(4) Lead-212: China's only company that can supply scientific research-level products.

(5) Radium-223: China's first engineered actinium-radium generator.

(6) Terbium-161: It has achieved small-scale market supply.

(7) Yttrium-90: It has the ability to supply in batches.

2. Application areas

This technology is mainly used to solve China's "bottleneck" problem of relying on imports for medical isotopes and to establish a stable supply guarantee system for Chinese medical isotopes.

3. Market prospects

The scale of China's radiopharmaceutical market will reach 9.3 billion yuan in 2025 and will grow to 26 billion yuan in 2030. The medical isotopes used to prepare radiopharmaceuticals are currently highly dependent on imports. In addition, in the current international trade environment, high-quality domestic medical isotopes are urgently needed to replace them, which can also be used for export overseas. It belongs to the blue ocean market.

4. Intellectual property

37 authorized patents and 47 accepted patents, all of which are held by the achievement units alone.

More information about REBIO GROUP's biomedicare service can be found here. If you are interested with such Product/Solution, please do not hesitate to contact us.